Seven and Eight Biopharmaceuticals Announces Acceptance of BDB001 in Combination with Pembrolizumab Interim Data to be Presented in a Poster Discussion at the 2021 ASCO Annual Meeting
EDISON, N.J.–(BUSINESS WIRE)–Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, today announced the acceptance of an abstract for a poster discussion presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract details additional interim safety and efficacy results for a phase 1 study of BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7/8) agonist, in combination with pembrolizumab in advanced solid tumors (NCT03486301).
“We are excited to share additional information about BDB001 in combination with pembrolizumab at the 2021 ASCO Annual Meeting,” said Dr. Robert H.I. Andtbacka, Chief Medical Officer, Seven and Eight Biopharma. “This builds upon the promising monotherapy data we reported on recently and helps illustrate the potential for BDB001 in combination with anti-PD-(L)1 therapies in difficult to treat tumors.”
The ASCO Annual Meeting will be held virtually on June 4-8, 2021 and showcases innovative scientific research in clinical oncology and advancements in cancer therapy.
Details on Seven and Eight Biopharma’s poster discussion presentation:
Abstract Title: BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7/8) agonist, in combination with pembrolizumab in advanced solid tumors: Phase 1 safety and efficacy results.
Session Title: Poster Discussion Session, Developmental Therapeutics—Immunotherapy
On-Demand Session Release Date and Time: 6/4/2021, 9:00 AM-10:00 AM
Abstract Number for Publication: 2512
This year, ASCO reviewed more than 5,400 abstracts for the 2021 ASCO Annual Meeting. More information about the meeting may be accessed at https://meetings.asco.org/am/ . According to ASCO’s Embargo Policy, abstracts will be released to the public on ASCO’s Meeting Library at 5:00 p.m. ET on May 19, 2021.
About Seven and Eight Biopharma
Seven and Eight Biopharmaceuticals Inc. is an Edison, New Jersey based, clinical stage biotechnology company focused on the development and commercialization of novel immunotherapies for cancer. The company specializes in TLR7/8 programs to treat cancer and has built a comprehensive global intellectual property portfolio in the category of toll-like receptor modulators. Managed by a seasoned team of professionals, the company is progressing a proprietary pipeline of cancer therapeutics in the U.S., with the lead product BDB001 in Phase I clinical trials in monotherapy and in combination with both anti-PD-1 and anti-PD-L1 monoclonal antibodies.
For more information, please visit www.7and8biopharma.com
Contacts
Robert Andtbacka, MD, CM
Chief Medical Officer
Seven and Eight Biopharmaceuticals Inc.
+1 (848) 300-0086
[email protected]
